Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Why Pfizer stock fell. Pfizer stock fell about 8% when the market opened on Dec. 13 in a knee-jerk reaction to forward-looking estimates that didn't align with Wall Street's predictions.

On Jan. 28, Citigroup Inc analyst Geoff Meacham reduced Pfizer's price target from $30 to $29 while maintaining a “Neutral” rating on the stock. The mean price target of $31.29 represents a ...

Pfizer Lifts Outlook as Company Seeks ... to significantly change the narrative on the stock, which we see as more likely in 2025 or beyond,” JPMorgan analyst Chris Schott wrote ...

The analyst anticipates that Pfizer’s management will guide to EPS in the mid-to-high $2 range with core business growth offset by the $0.30 in favorable but non-recurring items during 2024.

Bank of America Securities analyst Geoff Meacham has maintained their neutral stance on PFE stock, giving a Hold rating on May 24. Geoff Meacha ...

What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday ... to opine on 2025 ahead of the new year,” Goldman analyst writes. Price Action: PFE stock is down 0.39% at $25 ...